Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mario Lupia is active.

Publication


Featured researches published by Mario Lupia.


Journal of the American College of Cardiology | 2003

Left ventricular structural and functional characteristics in Cushing's syndrome.

Maria Lorenza Muiesan; Mario Lupia; Massimo Salvetti; Consuelo Grigoletto; Nicoletta Sonino; Marco Boscaro; Enrico Agabiti Rosei; Franco Mantero; Francesco Fallo

OBJECTIVES This study was designed to evaluate left ventricular (LV) anatomy and function in patients with Cushings syndrome. BACKGROUND A high prevalence of LV hypertrophy and concentric remodeling has been reported in Cushings syndrome, although no data have been reported on LV systolic and diastolic function. METHODS Forty-two consecutive patients with Cushings syndrome and 42 control subjects, matched for age, gender, and blood pressure, were studied. Left ventricular mass index (LVMI) and relative wall thickness (RWT) were measured by echocardiography, endocardial and midwall fractional shortening (FS) were assessed, and diastolic filling was measured by Doppler transmitral flow. RESULTS The RWT was significantly greater in Cushing patients than in controls. Left ventricular hypertrophy and concentric remodeling were observed in 10 and 26 patients with Cushings syndrome, respectively. In Cushing patients, midwall FS was significantly reduced compared with controls (16.2 +/- 3% vs. 21 +/- 4.5%, p = 0.01). The ratio of transmitral E and A flow velocities was reduced and E deceleration time was prolonged in Cushing patients compared with controls (p = 0.03 and p < 0.001, respectively). CONCLUSIONS In patients with Cushings syndrome, cardiac structural changes are associated with reduced midwall systolic performance and with diastolic dysfunction that may contribute to the high risk of cardiovascular events observed in these patients.


Nutrition Metabolism and Cardiovascular Diseases | 2009

Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension

Francesco Fallo; A. Dalla Pozza; Nicoletta Sonino; Mario Lupia; Francesco Tona; Giovanni Federspil; Mario Ermani; Cristiana Catena; Giorgio Soardo; L Di Piazza; Stella Bernardi; M Bertolotto; B Pinamonti; Bruno Fabris; La Sechi

BACKGROUND AND AIM Insulin resistance is recognized as the pathophysiological hallmark of non-alcoholic fatty liver disease (NAFLD). A relation between insulin sensitivity and left ventricular morphology and function has been reported in essential hypertension, where a high prevalence of NAFLD has been recently found. We investigated the inter-relationship between left ventricular morphology/function, metabolic parameters and NAFLD in 86 never-treated essential hypertensive patients subdivided in two subgroups according to the presence (n = 48) or absence (n = 38) of NAFLD at ultrasonography. METHODS AND RESULTS The two groups were similar as to sex, age and blood pressure levels. No patient had diabetes mellitus, obesity, hyperlipidemia, or other risk factors for liver disease. Body mass index, waist circumference, triglycerides, glucose, insulin, homeostasis model of assessment index for insulin resistance (HOMA-IR), aspartate aminotransferase and alanine aminotransferase were higher and adiponectin levels were lower in patients with NAFLD than in patients without NAFLD, and were associated with NAFLD at univariate analysis. Patients with NAFLD had similar prevalence of left ventricular hypertrophy compared to patients without NAFLD, but a higher prevalence of diastolic dysfunction (62.5 vs 21.1%, P < 0.001), as defined by E/A ratio <1 and E-wave deceleration time >220 ms. Diastolic dysfunction (P = 0.040) and HOMA-IR (P = 0.012) remained independently associated with NAFLD at backward multivariate analysis. CONCLUSIONS Non-alcoholic fatty liver disease was associated with insulin resistance and abnormalities of left ventricular diastolic function in a cohort of patients with essential hypertension, suggesting a concomitant increase of metabolic and cardiac risk in this condition.


Nephrology Dialysis Transplantation | 2012

Chest ultrasound and hidden lung congestion in peritoneal dialysis patients

Vincenzo Panuccio; Giuseppe Enia; Rocco Tripepi; Claudia Torino; Maurizio Garozzo; Giovanni Battaglia; Carmelita Marcantoni; Lorena Infantone; Guido Giordano; Maria Loreta De Giorgi; Mario Lupia; Vincenzo Bruzzese; Carmine Zoccali

BACKGROUND Chest ultrasound (US) is a non-invasive well-validated technique for estimating extravascular lung water (LW) in patients with heart diseases and in end-stage renal disease. We systematically applied this technique to the whole peritoneal dialysis (PD) population of five dialysis units. METHODS We studied the cross-sectional association between LW, echocardiographic parameters, clinical [pedal oedema, New York Heart Association (NYHA) class] and bioelectrical impedance analysis (BIA) markers of volume status in 88 PD patients. RESULTS Moderate to severe lung congestion was evident in 41 (46%) patients. Ejection fraction was the echocardiographic parameter with the strongest independent association with LW (r = -0.40 P = 0.002). Oedema did not associate with LW on univariate and multivariate analysis. NYHA class was slightly associated with LW (r = 0.21 P = 0.05). Among patients with severe lung congestion, only 27% had pedal oedema and the majority (57%) had no dyspnoea (NYHA Class I). Similarly, the prevalence of patients with BIA, evidence of volume excess was small (11%) and not significantly different (P = 0.79) from that observed in patients with mild or no congestion (9%). CONCLUSIONS In PD patients, LW by chest US reveals moderate to severe lung congestion in a significant proportion of asymptomatic patients. Intervention studies are necessary to prove the usefulness of chest US for optimizing the control of fluid excess in PD patients.


Journal of Endocrinological Investigation | 2009

Cardiovascular autonomic function in Cushing's syndrome

Francesco Fallo; Pietro Maffei; A. Dalla Pozza; M. Carli; P. Della Mea; Mario Lupia; Franco Rabbia; Nicoletta Sonino

Cardiac autonomic dysfunction is associated with increased cardiovascular mortality. No data on sympathovagal balance are available in patients with Cushing’s syndrome, in whom cardiovascular risk is high. We studied 10 patients with newly diagnosed Cushing’s syndrome (1 male/9 females; age mean±SD, 47±10 yr) and 10 control subjects matched for age, sex, body mass index, and cardiovascular risk factors. In both groups there were 7 patients with arterial hypertension, 3 with diabetes mellitus, and 2 with obesity. Cardiac autonomic function was evaluated by analysis of short-time heart rate variability (HRV) measures in frequency domain over 24-h, daytime, and nighttime. The 24-h ambulatory blood pressure monitoring and echocardiography were also performed. In comparison with controls, patients with Cushing’s syndrome had lower 24-h (1.3±0.6 vs 3.7±1.5, mean±SD, p<0.01), daytime (2.0±1.4 vs 4.5±1.6, p<0.01), and night-time (1.0±0.4 vs 3.5±2.3, p<0.01) low-frequency/high frequency (LF/HF) power ratio. In the presence of similar LF power, the difference was due to elevation in HF power in Cushing’s syndrome compared to controls: 24-h, 12.7±6.7 vs 5.8±2.8, p<0.01; daytime, 10.2±7.3 vs 4.5±2.1, p<0.05; nighttime, 14.2±7.0 vs 7.8±4.7, p<0.05. Eight Cushing patients vs 4 controls had a non-dipping blood pressure profile. At echocardiography, Cushing patients had a greater left ventricular mass index and/or relative wall thickness, and impaired diastolic function, compared with controls. Compared to controls, patients with Cushing’s syndrome showed a sympathovagal imbalance, characterized by a relatively increased parasympathetic activity. Whether this autonomic alteration is meant to counterbalance cortisol-induced effects on blood pressure and cardiac structure/function or has a different pathophysiological significance is still unknown.


Life Sciences | 2016

Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.

Lorenzo A. Calò; Ugo Vertolli; Elisa Pagnin; Verdiana Ravarotto; Paul A. Davis; Mario Lupia; Elena Naso; Giuseppe Maiolino; Agostino Naso

AIMS Cardiovascular disease (CVD) is the leading cause of excess mortality in chronic kidney disease (CKD) and dialysis patients (DP) who have higher prevalence of left ventricular hypertrophy (LVH), the strongest predictor of CV events. Rho kinase (ROCK) activation is linked in hypertensive patients to cardiac remodeling while ROCK inhibition suppresses cardiomyocyte hypertrophy and, in a human clinical condition opposite to hypertension, its downregulation associates with lack of CV remodeling. Information on ROCK activation-LVH link in CKD and DP is lacking. MATERIALS AND METHODS Mononuclear cells (PBMCs) MYPT-1 phosphorylation, a marker of ROCK activity, and the effect of fasudil, a ROCK inhibitor, on MYPT-1 phosphorylation were assessed in 23 DPs, 13 stage 3-4 CKD and 36 healthy subjects (HS) by Western blot. LV mass was assessed by M-mode echocardiography. KEY FINDINGS DP and CKD had higher MYPT-1 phosphorylation compared to HS (p<0.001 and p=0.003). Fasudil (500 and 1000μM) dose dependently reduced MYPT-1 phosphorylation in DP (p<0.01). DP had higher LV mass than CKD (p<0.001). MYPT-1 phosphorylation was higher in patients with LVH (p=0.009) and correlated with LV mass both in DP and CKD with LVH (p<0.001 and p=0.006). SIGNIFICANCE In DP and CKD, ROCK activity tracks with LVH. This ROCK activation-LVH link provided in these CVD high-risk patients along with similar findings in hypertensive patients and added to opposite findings in a human model opposite to hypertension and in type 2 diabetic patients, identify ROCK activation as a potential LVH marker and provide further rationale for ROCK activation inhibition as target of therapy in CVD high-risk patients.


Clinical Nutrition | 2014

Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients

Lorenzo A. Calò; Ugo Vertolli; Paul A. Davis; Lucia Dal Maso; Elisa Pagnin; Verdiana Ravarotto; Giuseppe Maiolino; Mario Lupia; Teresa Maria Seccia; Gian Paolo Rossi

BACKGROUND & AIMS Cardiovascular disease, the most common cause for morbidity and mortality in end-stage renal disease (ESRD), has prompted the exploration of multiple approaches to improve outcomes. Cardiovascular risk factors such as oxidative stress (OxSt) and cardiac remodelling are common in ESRD and dialysis patients. Green tea (GT) is well recognized as reducing OxSt. This 6 months study evaluated in 20 ESRD patients under chronic dialysis, the effect of GT treatment (1 g/day as commercially available capsule) on cellular and plasma OxSt and proliferation related markers using a molecular biology approach. METHODS Mononuclear cell p22(phox), Haeme Oxygenase (HO)-1 protein expression, and phosphorylated ERK1/2 status were evaluated in dialysis patients at baseline, after 3 and 6 months of GT treatment by Western blot analysis and plasma oxLDL by ELISA. Cardiac remodelling was assessed by echocardiographic left ventricular (LV) mass determination at baseline and at the end of the study. RESULTS GT treatment reduced p22(phox) and pERK1/2 from baseline while HO-1 increased. At baseline, LV mass correlated with both p22(phox) and oxLDL. GT treatment decreased LV mass from baseline, which correlated with oxLDL. 9 patients had LV hypertrophy at baseline, which, at 6 months, was normalized in 5 and reduced in 3, showing a parallel decrease of p22(phox), pERK1/2, oxLDL and increase of HO-1. CONCLUSIONS Treatment with GT decreased the expression of OxSt-related proteins tightly associated with cardiovascular disease and decreased LV mass. It appears highly likely that the addition of GT can provide a benefit in terms of cardiovascular protection in dialysis patients.


Nutrition Metabolism and Cardiovascular Diseases | 2012

Low serum 25-hydroxyvitamin D levels are associated with left ventricular hypertrophy in essential hypertension

Francesco Fallo; Cristiana Catena; Valentina Camozzi; G. Luisetto; C. Cosma; M. Plebani; Mario Lupia; Francesco Tona; Leonardo A. Sechi

BACKGROUND AND AIM Low serum 25-hydroxyvitamin D [25(OH)D] levels may have an important role in predisposing to hypertension and myocardial disease. We investigated the relationship between 25(OH)D and left ventricular (LV) structure and function, assessed by echocardiography, in a series of patients with essential hypertension (EH). METHODS AND RESULTS Sixty-two newly diagnosed never-treated patients (32 male/30 female), aged 18-65 years, with grade 1-2 hypertension, no diabetes, no obesity, no hyperlipidemia, and no cardiopulmonary, renal, or hepatic disease, were studied. Twenty-four healthy normotensive sex-, age-, BMI-matched subjects served as controls. Hypertensive patients with 25(OH)D deficiency, defined as serum 25(OH)D levels <50 nmol/L, had higher prevalence of LV hypertrophy (LVH) than their 25(OH)D-sufficient counterparts (57.1 vs 17.6%, P = 0.02); no differences between the two groups were found in blood pressure levels as well as in other biochemical and hormone parameters. There was an inverse correlation between LV mass index and 25(OH)D levels (r = -0.366, P < 0.003) and a direct correlation between LV mass index and BMI (r = 0.333, P < 0.006) in the entire hypertensive population. The two variables remained independently associated with LVH at multivariable logistic regression analysis (OR 1.05, P < 0.005 and OR 1.25, P = 0.03, respectively). Prevalence of 25(OH)D deficiency was similar in EH patients and controls (45.1 vs 41.6%, P = 0.89), whereas no correlation between echocardiographic parameters and hormone levels was found. CONCLUSIONS In the absence of major cardiovascular risk factors, 25(OH)D deficiency is a frequent finding in EH patients and is independently associated with LVH.


American Journal of Hypertension | 2005

Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients

Paolo Della Mea; Mario Lupia; Valentina Bandolin; Samuele Guzzon; Nicoletta Sonino; Roberto Vettor; Francesco Fallo


European Journal of Endocrinology | 1999

Regression of cardiac abnormalities after replacement therapy in Addison's disease

Francesco Fallo; Corrado Betterle; S Budano; Mario Lupia; Marco Boscaro; Nicoletta Sonino


Nephrology Dialysis Transplantation | 2016

MP547INCREASED RHO KINASE ACTIVITY IN DIALYSIS AND STAGE 3-4 CHRONIC KIDNEY DISEASE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY: CARDIOVASCULAR RISK IMPLICATIONS

Lorenzo A. Calò; Ugo Vertolli; Elena Naso; Elisa Pagnin; Verdiana Ravarotto; Mario Lupia; Agostino Naso

Collaboration


Dive into the Mario Lupia's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge